Exact Mass: 401.27185000000003
Exact Mass Matches: 401.27185000000003
Found 456 metabolites which its exact mass value is equals to given mass value 401.27185000000003,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Myriocin
An amino acid-based antibiotic derived from certain thermophilic fungi; acts as a potent inhibitor of serine palmitoyltransferase, the first step in sphingosine biosynthesis. Myriocin also possesses immunosuppressant activity. D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D000890 - Anti-Infective Agents > D000935 - Antifungal Agents [Raw Data] CBA29_Myriocin_pos_20eV_1-3_01_1557.txt [Raw Data] CBA29_Myriocin_neg_40eV_1-3_01_1590.txt [Raw Data] CBA29_Myriocin_pos_10eV_1-3_01_1546.txt [Raw Data] CBA29_Myriocin_neg_30eV_1-3_01_1589.txt [Raw Data] CBA29_Myriocin_pos_40eV_1-3_01_1559.txt [Raw Data] CBA29_Myriocin_pos_30eV_1-3_01_1558.txt [Raw Data] CBA29_Myriocin_pos_50eV_1-3_01_1560.txt [Raw Data] CBA29_Myriocin_neg_10eV_1-3_01_1578.txt [Raw Data] CBA29_Myriocin_neg_20eV_1-3_01_1588.txt Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC50 of 3.5 μg/mL for inhibiting HCV infection[1][2][3].
6'-Hydroxybuspirone
6-Hydroxybuspirone is a metabolite of buspirone. Buspirone is an anxiolytic psychoactive drug of the azapirone chemical class, and is primarily used to treat generalized anxiety disorder (GAD) Bristol-Myers Squibb (BMS) gained FDA approval of buspirone in 1986 for treatment of GAD. The patent on Buspar by Bristol-Myers Squibb expired in 2001, and buspirone is available as a generic. (Wikipedia)
Buspirone N-oxide
Buspirone N-oxide is a metabolite of buspirone. Buspirone is an anxiolytic psychoactive drug of the azapirone chemical class, and is primarily used to treat generalized anxiety disorder (GAD) Bristol-Myers Squibb (BMS) gained FDA approval of buspirone in 1986 for treatment of GAD. The patent on Buspar by Bristol-Myers Squibb expired in 2001, and buspirone is available as a generic. (Wikipedia)
3'-Hydroxybuspirone
3-Hydroxybuspirone is a metabolite of buspirone. Buspirone is an anxiolytic psychoactive drug of the azapirone chemical class, and is primarily used to treat generalized anxiety disorder (GAD) Bristol-Myers Squibb (BMS) gained FDA approval of buspirone in 1986 for treatment of GAD. The patent on Buspar by Bristol-Myers Squibb expired in 2001, and buspirone is available as a generic. (Wikipedia)
5-Hydroxybuspirone
5-Hydroxybuspirone is a metabolite of buspirone. Buspirone is an anxiolytic psychoactive drug of the azapirone chemical class, and is primarily used to treat generalized anxiety disorder (GAD) Bristol-Myers Squibb (BMS) gained FDA approval of buspirone in 1986 for treatment of GAD. The patent on Buspar by Bristol-Myers Squibb expired in 2001, and buspirone is available as a generic. (Wikipedia)
3-hydroxypentadecanoyl carnitine
C22H43NO5 (401.31410680000005)
3-Hydroxypentadecanoyl carnitine is an acylcarnitine. More specifically, it is an 3-hydroxypentadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxypentadecanoyl carnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-hydroxypentadecanoyl carnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
O-(13-Carboxytridecanoyl)carnitine
O-(13-Carboxytridecanoyl)carnitine is an acylcarnitine. More specifically, it is an tetradecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. O-(13-Carboxytridecanoyl)carnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine O-(13-Carboxytridecanoyl)carnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
10-Hydroxypentadecanoylcarnitine
C22H43NO5 (401.31410680000005)
10-Hydroxypentadecanoylcarnitine is an acylcarnitine. More specifically, it is an 10-hydroxypentadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-Hydroxypentadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 10-Hydroxypentadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
7-Hydroxypentadecanoylcarnitine
C22H43NO5 (401.31410680000005)
7-Hydroxypentadecanoylcarnitine is an acylcarnitine. More specifically, it is an 7-hydroxypentadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Hydroxypentadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-Hydroxypentadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
9-Hydroxypentadecanoylcarnitine
C22H43NO5 (401.31410680000005)
9-Hydroxypentadecanoylcarnitine is an acylcarnitine. More specifically, it is an 9-hydroxypentadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-Hydroxypentadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 9-Hydroxypentadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
6-Hydroxypentadecanoylcarnitine
C22H43NO5 (401.31410680000005)
6-Hydroxypentadecanoylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxypentadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Hydroxypentadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 6-Hydroxypentadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
5-Hydroxypentadecanoylcarnitine
C22H43NO5 (401.31410680000005)
5-Hydroxypentadecanoylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxypentadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxypentadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 5-Hydroxypentadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Arachidonoyl Proline
C25H39NO3 (401.29297840000004)
N-arachidonoyl proline belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Arachidonic acid amide of Proline. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Arachidonoyl Proline is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Arachidonoyl Proline is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
N-Eicosapentaenoyl Valine
C25H39NO3 (401.29297840000004)
N-eicosapentaenoyl valine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Eicosapentaenoic acid amide of Valine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Eicosapentaenoyl Valine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Eicosapentaenoyl Valine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
(2S,3R,4R)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid
5-Methylurapidil
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
Isoquinoline, 1,2,3,4-tetrahydro-2-(4-amino-6-((4-phenyl-1-piperazinyl)methyl)-s-triazin-2-yl)-
Amperozide
C23H29F2N3O (401.22785680000004)
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent Amperozide is an atypical antipsychotic that acts as an antagonist of the 5-HT2 receptor with a Ki value of 26 nM. Amperozide has a low affinity for D2 receptors[1].
Anisperimus
C18H39N7O3 (401.31142239999997)
Cetilistat
C25H39NO3 (401.29297840000004)
C471 - Enzyme Inhibitor > C29715 - Gastrointestinal Lipase Inhibitor D057847 - Lipid Regulating Agents D019440 - Anti-Obesity Agents D004791 - Enzyme Inhibitors
[2-Amino-2-(hydroxymethyl)-5-(4-octylphenyl)pentyl] dihydrogen phosphate
C20H36NO5P (401.23309760000006)
N-Allm
C19H35N3O4S (401.2348150000001)
(3E,9E)-5-Hydroxy-14-isobutyl-9,12,13-trimethyl-6,7,8,10a,13,13a,14,15-octahydro-2H-oxacyclododecino[2,3-d]isoindole-2,16(5H)-dione
C24H35NO4 (401.25659500000006)
12-epi-15-O-acetylnapelline|12-epi-lucidusculine
C24H35NO4 (401.25659500000006)
3(R)-Benzoyloxy-2(R)-methyl-6(R)-(11-oxododecyl)-piperidine
C25H39NO3 (401.29297840000004)
C24H35NO4_1H-Cycloundec[d]isoindole-1,15(2H)-dione, 3,3a,4,6a,9,10,11,12-octahydro-11,12-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-, (7E,13E)
C24H35NO4 (401.25659500000006)
C25H39NO3_(7E)-3-Isobutyl-13-methoxy-4,5,8-trimethyl-3,3a,4,6a,9,10,11,12,13,14-decahydro-1H-cycloundeca[d]isoindole-1,15(2H)-dione
C25H39NO3 (401.29297840000004)
C24H35NO4_(1S,2R,3R,6S,7R,8S,11S,14S,15S,18R)-18-Hydroxy-8-isobutyl-5,6,15-trimethyl-19-oxa-9-azapentacyclo[13.3.1.0~2,14~.0~3,11~.0~7,11~]nonadec-4-ene-10,12-dione
C24H35NO4 (401.25659500000006)
6-hydroxy-9,12,13-trimethyl-14-(2-methylpropyl)-2H,5H,6H,7H,8H,13H,13aH,14H,15H,16H,16bH-oxacyclododeca[3,2-e]isoindole-2,16-dione
C24H35NO4 (401.25659500000006)
(Z)-N-hexadec-9-enoyl-L-phenylalanine
C25H39NO3 (401.29297840000004)
Ala Ala Ile Lys
C18H35N5O5 (401.26380600000005)
Ala Ala Ile Gln
Ala Ala Lys Ile
C18H35N5O5 (401.26380600000005)
Ala Ala Lys Leu
C18H35N5O5 (401.26380600000005)
Ala Ala Leu Lys
C18H35N5O5 (401.26380600000005)
Ala Ala Leu Gln
Ala Ala Gln Ile
Ala Ala Gln Leu
Ala Gly Arg Val
Ala Gly Val Arg
Ala Ile Ala Lys
C18H35N5O5 (401.26380600000005)
Ala Ile Ala Gln
Ala Ile Lys Ala
C18H35N5O5 (401.26380600000005)
Ala Ile Gln Ala
Ala Lys Ala Ile
C18H35N5O5 (401.26380600000005)
Ala Lys Ala Leu
C18H35N5O5 (401.26380600000005)
Ala Lys Ile Ala
C18H35N5O5 (401.26380600000005)
Ala Lys Leu Ala
C18H35N5O5 (401.26380600000005)
Ala Lys Pro Ser
Ala Lys Ser Pro
Ala Leu Ala Lys
C18H35N5O5 (401.26380600000005)
Ala Leu Ala Gln
Ala Leu Lys Ala
C18H35N5O5 (401.26380600000005)
Ala Leu Gln Ala
Ala Asn Val Val
Ala Pro Lys Ser
Ala Pro Ser Lys
Ala Gln Ala Ile
Ala Gln Ala Leu
Ala Gln Ile Ala
Ala Gln Leu Ala
Ala Arg Gly Val
Ala Arg Val Gly
Ala Ser Lys Pro
Ala Ser Pro Lys
Ala Val Gly Arg
Ala Val Asn Val
Ala Val Arg Gly
Ala Val Val Asn
Gly Ala Arg Val
Gly Ala Val Arg
Gly Gly Ile Arg
Gly Gly Leu Arg
Gly Gly Arg Ile
Gly Gly Arg Leu
Gly Ile Gly Arg
Gly Ile Asn Val
Gly Ile Arg Gly
Gly Ile Val Asn
Gly Lys Pro Thr
Gly Lys Thr Pro
Gly Lys Val Val
C18H35N5O5 (401.26380600000005)
Gly Leu Gly Arg
Gly Leu Asn Val
Gly Leu Arg Gly
Gly Leu Val Asn
Gly Asn Ile Val
Gly Asn Leu Val
Gly Asn Val Ile
Gly Asn Val Leu
Gly Pro Lys Thr
Gly Pro Thr Lys
Gly Gln Val Val
Gly Arg Ala Val
Gly Arg Gly Ile
Gly Arg Gly Leu
Gly Arg Ile Gly
Gly Arg Leu Gly
Gly Arg Val Ala
Gly Thr Lys Pro
Gly Thr Pro Lys
Gly Val Ala Arg
Gly Val Ile Asn
Gly Val Lys Val
C18H35N5O5 (401.26380600000005)
Gly Val Leu Asn
Gly Val Asn Ile
Gly Val Asn Leu
Gly Val Gln Val
Gly Val Arg Ala
Gly Val Val Lys
C18H35N5O5 (401.26380600000005)
Gly Val Val Gln
Ile Ala Ala Lys
C18H35N5O5 (401.26380600000005)
Ile Ala Ala Gln
Ile Ala Lys Ala
C18H35N5O5 (401.26380600000005)
Ile Ala Gln Ala
Ile Gly Gly Arg
Ile Gly Asn Val
Ile Gly Arg Gly
Ile Gly Val Asn
Ile Lys Ala Ala
C18H35N5O5 (401.26380600000005)
Ile Asn Gly Val
Ile Asn Val Gly
Ile Gln Ala Ala
Ile Arg Gly Gly
Ile Val Gly Asn
Ile Val Asn Gly
Lys Ala Ala Ile
C18H35N5O5 (401.26380600000005)
Lys Ala Ala Leu
C18H35N5O5 (401.26380600000005)
Lys Ala Ile Ala
C18H35N5O5 (401.26380600000005)
Lys Ala Leu Ala
C18H35N5O5 (401.26380600000005)
Lys Ala Pro Ser
Lys Ala Ser Pro
Lys Gly Pro Thr
Lys Gly Thr Pro
Lys Gly Val Val
C18H35N5O5 (401.26380600000005)
Lys Ile Ala Ala
C18H35N5O5 (401.26380600000005)
Lys Leu Ala Ala
C18H35N5O5 (401.26380600000005)
Lys Pro Ala Ser
Lys Pro Gly Thr
Lys Pro Ser Ala
Lys Pro Thr Gly
Lys Ser Ala Pro
Lys Ser Pro Ala
Lys Thr Gly Pro
Lys Thr Pro Gly
Lys Val Gly Val
C18H35N5O5 (401.26380600000005)
Lys Val Val Gly
C18H35N5O5 (401.26380600000005)
Leu Ala Ala Lys
C18H35N5O5 (401.26380600000005)
Leu Ala Ala Gln
Leu Ala Lys Ala
C18H35N5O5 (401.26380600000005)
Leu Ala Gln Ala
Leu Gly Gly Arg
Leu Gly Asn Val
Leu Gly Arg Gly
Leu Gly Val Asn
Leu Lys Ala Ala
C18H35N5O5 (401.26380600000005)
Leu Asn Gly Val
Leu Asn Val Gly
Leu Gln Ala Ala
Leu Arg Gly Gly
Leu Val Gly Asn
Leu Val Asn Gly
Asn Ala Val Val
Asn Gly Ile Val
Asn Gly Leu Val
Asn Gly Val Ile
Asn Gly Val Leu
Asn Ile Gly Val
Asn Ile Val Gly
Asn Leu Gly Val
Asn Leu Val Gly
Asn Val Ala Val
Asn Val Gly Ile
Asn Val Gly Leu
Asn Val Ile Gly
Asn Val Leu Gly
Asn Val Val Ala
Pro Ala Lys Ser
Pro Ala Ser Lys
Pro Gly Lys Thr
Pro Gly Thr Lys
Pro Lys Ala Ser
Pro Lys Gly Thr
Pro Lys Ser Ala
Pro Lys Thr Gly
Pro Ser Ala Lys
Pro Ser Lys Ala
Pro Thr Gly Lys
Pro Thr Lys Gly
Gln Ala Ala Ile
Gln Ala Ala Leu
Gln Ala Ile Ala
Gln Ala Leu Ala
Gln Gly Val Val
Gln Ile Ala Ala
Gln Leu Ala Ala
Gln Val Gly Val
Gln Val Val Gly
Arg Ala Gly Val
Arg Ala Val Gly
Arg Gly Ala Val
Arg Gly Gly Ile
Arg Gly Gly Leu
Arg Gly Ile Gly
Arg Gly Leu Gly
Arg Gly Val Ala
Arg Ile Gly Gly
Arg Leu Gly Gly
Arg Val Ala Gly
Arg Val Gly Ala
Ser Ala Lys Pro
Ser Ala Pro Lys
Ser Lys Ala Pro
Ser Lys Pro Ala
Ser Pro Ala Lys
Ser Pro Lys Ala
Thr Gly Lys Pro
Thr Gly Pro Lys
Thr Lys Gly Pro
Thr Lys Pro Gly
Thr Pro Gly Lys
Thr Pro Lys Gly
Val Ala Gly Arg
Val Ala Asn Val
Val Ala Arg Gly
Val Ala Val Asn
Val Gly Ala Arg
Val Gly Ile Asn
Val Gly Lys Val
C18H35N5O5 (401.26380600000005)
Val Gly Leu Asn
Val Gly Asn Ile
Val Gly Asn Leu
Val Gly Gln Val
Val Gly Arg Ala
Val Gly Val Lys
C18H35N5O5 (401.26380600000005)
Val Gly Val Gln
Val Ile Gly Asn
Val Ile Asn Gly
Val Lys Gly Val
C18H35N5O5 (401.26380600000005)
Val Lys Val Gly
C18H35N5O5 (401.26380600000005)
Val Leu Gly Asn
Val Leu Asn Gly
Val Asn Ala Val
Val Asn Gly Ile
Val Asn Gly Leu
Val Asn Ile Gly
Val Asn Leu Gly
Val Asn Val Ala
Val Gln Gly Val
Val Gln Val Gly
Val Arg Ala Gly
Val Arg Gly Ala
Val Val Ala Asn
Val Val Gly Lys
C18H35N5O5 (401.26380600000005)
Val Val Gly Gln
Val Val Lys Gly
C18H35N5O5 (401.26380600000005)
Val Val Asn Ala
Val Val Gln Gly
PGF2alpha-EA(d4)
C22H35D4NO5 (401.30791711200004)
CAR 14:1;O2
p-dodecylbenzenesulphonic acid, compound with 1-aminopropan-2-ol (1:1)
C21H39NO4S (401.25996540000006)
(3S,4aS,8aS)-2-[(3S)-3-amino-2-hydroxy-4-phenylbutyl]-N-tert-butyl-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide
biperiden lactate
C24H35NO4 (401.25659500000006)
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent
4-Hydroxy-alpha1-[[[6-(3-phenylpropoxy)hexyl]amino]methyl]-1,3-benzenedimethanol
C24H35NO4 (401.25659500000006)
ALLM (Calpain Inhibitor)
C19H35N3O4S (401.2348150000001)
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D007976 - Leupeptins
[[1-[N-Hydroxy-acetamidyl]-3-methyl-butyl]-carbonyl-leucinyl]-alanine ethyl ester
C19H35N3O6 (401.25257300000004)
4-(3,4-dihydro-2H-quinolin-1-yl)-6-[(4-phenyl-1-piperazinyl)methyl]-1,3,5-triazin-2-amine
Cetilistat
C25H39NO3 (401.29297840000004)
C471 - Enzyme Inhibitor > C29715 - Gastrointestinal Lipase Inhibitor D057847 - Lipid Regulating Agents D019440 - Anti-Obesity Agents D004791 - Enzyme Inhibitors
Dehydrocholate
C24H33O5- (401.23278680000004)
D005765 - Gastrointestinal Agents > D002756 - Cholagogues and Choleretics D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
Acrichine
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000871 - Anthelmintics D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors
(E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-icos-6-enoic acid
1-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]pyrrolidine-2-carboxylic acid
C25H39NO3 (401.29297840000004)
ALLM
C19H35N3O4S (401.2348150000001)
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015853 - Cysteine Proteinase Inhibitors
[1-(3-Phenoxypropyl)-4-piperidinyl]-diphenylmethanol
1-ethyl-4-hydroxy-2-oxo-N-(1-oxodecyl)-3-quinolinecarbohydrazide
C22H31N3O4 (401.23144460000003)
(3E,9E)-5,6-Dihydroxy-9,13,14-trimethyl-16-(2-methylpropyl)-17-azatricyclo[9.7.0.01,15]octadeca-3,9,12-triene-2,18-dione
C24H35NO4 (401.25659500000006)
(1S,2R,3R,6S,7R,8S,11S,14S,15S,18R)-18-hydroxy-5,6,15-trimethyl-8-(2-methylpropyl)-19-oxa-9-azapentacyclo[13.3.1.02,14.03,11.07,11]nonadec-4-ene-10,12-dione
C24H35NO4 (401.25659500000006)
5,6-dimethyl-2-[1-[[1-(phenylmethyl)-5-tetrazolyl]methyl]-4-piperidinyl]-1H-benzimidazole
N-cyclopropyl-1-[1-[[5-(2-methylpropyl)-1H-pyrazol-3-yl]-oxomethyl]-4-piperidinyl]-4-piperidinecarboxamide
1-[2-[[(2,3-dihydro-1H-inden-5-ylamino)-oxomethyl]amino]-2-methyl-1-oxopropyl]-4-piperidinecarboxylic acid ethyl ester
C22H31N3O4 (401.23144460000003)
(9E)-4-Methoxy-9,13,14-trimethyl-16-(2-methylpropyl)-17-azatricyclo[9.7.0.01,15]octadeca-9,12-diene-2,18-dione
C25H39NO3 (401.29297840000004)
Crambescidin 401
C22H31N3O4 (401.23144460000003)
An organic heteropentacyclic guanidine alkaloid isolated from the marine sponge Crambe crambe.
(2R,3R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C22H31N3O4 (401.23144460000003)
(2R,3S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C22H31N3O4 (401.23144460000003)
(2S,3R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C22H31N3O4 (401.23144460000003)
(2S,3R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C22H31N3O4 (401.23144460000003)
2-[(2S,3R,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide
C22H31N3O4 (401.23144460000003)
2-[(2S,3S,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide
C22H31N3O4 (401.23144460000003)
(2R,3S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C22H31N3O4 (401.23144460000003)
(2S,3S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C22H31N3O4 (401.23144460000003)
2-[(2S,3R,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide
C22H31N3O4 (401.23144460000003)
2-[(2R,3S,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide
C22H31N3O4 (401.23144460000003)
2-[(2R,3S,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide
C22H31N3O4 (401.23144460000003)
2-[(2R,3R,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide
C22H31N3O4 (401.23144460000003)
2-[(2S,3S,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide
C22H31N3O4 (401.23144460000003)
2-[(2R,3R,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide
C22H31N3O4 (401.23144460000003)
16-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]hexadecanoate
(E,3S,4S)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid
15-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxopentadecanoate
15-(3,5-Dihydroxy-6-methyloxan-2-yl)oxyhexadecanoate
(14R)-14-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxopentadecanoate
(3Z,9Z)-5,6-dihydroxy-9,13,14-trimethyl-16-(2-methylpropyl)-17-azatricyclo[9.7.0.01,15]octadeca-3,9,12-triene-2,18-dione
C24H35NO4 (401.25659500000006)
Amperozide
C23H29F2N3O (401.22785680000004)
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent Amperozide is an atypical antipsychotic that acts as an antagonist of the 5-HT2 receptor with a Ki value of 26 nM. Amperozide has a low affinity for D2 receptors[1].
O-(13-carboxytridecanoyl)carnitine
An O-acylcarnitine having 13-carboxytridecanoyl as the acyl substituent.
oscr#28(1-)
A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#28, obtained by deprotonation of the carboxy group; major species at pH 7.3.
Ro 64-6198
Ro 64-6198 is a potent, selective, nonpeptide, high-affinity, high cellular permeability and brain penetration N/OFQ receptor (NOP) agonist with an EC50 value of 25.6 nM. Ro 64-6198 is at least 100 times more selective for the NOP receptor over the classic opioid receptors. Ro 64-6198 can be used for stress and anxiety, addiction, neuropathic pain, cough, and anorexia[1][2].
(1'r,2s,2's,4's,8'r,9's,13's,16's,18's)-16'-amino-9',13'-dimethyl-5'-oxaspiro[oxolane-2,7'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-5,6'-dione
C24H35NO4 (401.25659500000006)
1,11,12-trihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one
C24H35NO4 (401.25659500000006)
(5s,10as,13s,13as,14s,16ar)-5,16-dihydroxy-9,12,13-trimethyl-14-(2-methylpropyl)-5h,6h,7h,8h,10ah,13h,13ah,14h-oxacyclododeca[3,2-d]isoindol-2-one
C24H35NO4 (401.25659500000006)
(1r,2s,3s,6r,7s,8r,11s,14r,15r,16s)-10,16-dihydroxy-1,5,6-trimethyl-8-(2-methylpropyl)-19-oxa-9-azapentacyclo[13.3.1.0²,¹⁴.0³,¹¹.0⁷,¹¹]nonadeca-4,9-dien-12-one
C24H35NO4 (401.25659500000006)
(1r,2r,4s,5r,7r,8r,9r,10r,13r,16s,17r)-11-ethyl-7,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
C24H35NO4 (401.25659500000006)
(3s,3ar,4s,6ar,13r,15ar)-1,13-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,13h,14h-cycloundeca[d]isoindole-12,15-dione
C24H35NO4 (401.25659500000006)
(1r,2r,4s,5r,7r,8r,9r,10r,13r,16s,17r)-11-ethyl-4,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-7-yl acetate
C24H35NO4 (401.25659500000006)
(3s,3ar,4s,6as,11s,12r,15ar)-1,11,12-trihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one
C24H35NO4 (401.25659500000006)
(1r,5r,8r,10r,11r,12s,14s,16r,17r)-7-(2-hydroxyethyl)-5-methyl-13-methylidene-9-oxa-7-azahexacyclo[8.6.2.2¹¹,¹⁴.0¹,⁸.0⁵,¹⁷.0¹¹,¹⁶]icosan-12-yl acetate
C24H35NO4 (401.25659500000006)